Table 3.
CC | CC-PP |
p Value (CC vs CC-PP) |
|||||||
---|---|---|---|---|---|---|---|---|---|
Metabolite | Cmax (µM) |
Tmax (h) |
AUC (µM min−1) |
Cmax (µM) |
Tmax (h) |
AUC (µM min−1) |
Cmax | Tmax | AUC |
Intestinal absorption | |||||||||
Epicatechin-3′-glucuronide | 0.025 ± 0.001 | 1.5 ± 0.5 | 0.072 ± 0.028 | 0.037 ± 0.001 | 1.4 ± 0.8 | 0.110 ± 0.066 | <0.05 | N.S. | N.S. |
Epicatechin-3′-sulfate | 0.026 ± 0.003 | 1.0 ± 0.1 | 0.101 ± 0.023 | 0.042 ± 0.004 | 1.2 ± 0.5 | 0.109 ± 0.076 | N.S. | N.S. | N.S. |
Epicatechin-methoxy-sulfate (isomer 1) | 0.031 ± 0.003 | 1.3 ± 0.6 | 0.122 ± 0.025 | 0.041 ± 0.002 | 1.1 ± 0.6 | 0.173 ± 0.107 | <0.05 | N.S. | N.S. |
Epicatechin-methoxy-sulfate (isomer 2) | N.D. | 0.041 ± 0.004 | 1.3 ± 0.5 | 0.145 ± 0.107 | <0.05 | <0.05 | <0.05 | ||
Microbial metabolites | |||||||||
DHPVL | 0.035 ± 0.008 | 6.0 ± 1.6 | 0.124 ± 0.073 | 0.037 ± 0.007 | 5.5 ± 1.4 | 0.192 ± 0.029 | N.S. | N.S. | N.S. |
HPVL-3′-glucuronide | 0.031 ± 0.004 | 5.6 ± 0.8 | 0.106 ± 0.021 | 0.357 ± 0.200 | 5.0 ± 1.2 | 1.433 ± 0.727 | <0.05 | N.S. | <0.05 |
HPVL-sulfate | 0.336 ± 0.240 | 5.3 ± 2.4 | 1.150 ± 0.742 | 0.332 ± 0.161 | 4.9 ± 1.2 | 1.384 ± 0.648 | N.S. | N.S. | N.S. |
PVL-methoxy-glucuronide | 0.022 ± 0.001 | 5.3 ± 1.0 | 0.078 ± 0.032 | 0.027 ± 0.003 | 5.6 ± 1.3 | 0.091 ± 0.059 | <0.05 | N.S. | N.S. |
PVL-3′-sulfate b | Traces | (4–6) a | 0.039 ± 0.014 | 5.2 ± 2.2 | 0.161 ± 0.105 | <0.05 | <0.05 | <0.05 | |
HHPVA-sulfate | N.D. | 0.037 ± 0.008 | 6.3 ± 1.8 | 0.167 ± 0.068 | <0.05 | <0.05 | <0.05 |
AUC: area under the curve; DHPVL: 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone; HPVL: 5-(3′-hydroxyphenyl)-γ-valerolactone; PVL: 5-phenyl-γ-valerolactone; HDHPVA: 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid; N.D.: Not detected; N.S.: Non-significant differences; p values were assessed using the general linear model of variance for repeated measures. a Range where the metabolite showed the highest value. b No pharmacokinetic parameters of these metabolites were determined because they were present at trace levels.